Document is current
Any future updates will be listed below
-
Authors
Mehta, Rohtesh S.
Aljawai, Yosra M.
Fingrut, Warren
Smallbone, Portia
Rondon, Gabriela
Olson, Amanda
Oran, Betul
Kebriaei, Partow
Champlin, Richard E.
Shpall, Elizabeth J.
- License Information
-
More Information
Article History
Received: 15 February 2026
Accepted: 9 April 2026
First Online: 20 April 2026
Declarations
:
: The study was approved by the MD Anderson Cancer Center Institutional Review Board (2025‑0916) with a waiver of informed consent and HIPAA authorization, and was conducted in accordance with the Declaration of Helsinki.
: All authors provide the consent for the publication. Our manuscript does not contain data from any individual person.
: R.S.M. served as a consultant reviewer for OrcaBio and received honorarium from Lumanity for providing Expert Opinion. E.J.S. serves as a consultant for Cimeio Therapeutics AG, New York Blood Center, Celaid Therapeutics Inc, Scientific Advisor for Adaptimmune Limited, Navan Technologie, Axio Research, FibroBiologics, is on the Board of Directors/Management for National Marrow Donor Program, and License agreement for Affimed, Takeda, Rege Nexus, and is a speaker for Dava Oncology. K.R. and The University of Texas MD Anderson Cancer Center have an institutional financial conflict of interest with Takeda Pharmaceutical and Affimed GmbH. K.R. participates on the Scientific Advisory Board for Avenge Bio, Virogin Biotech, Navan Technologies, Caribou Biosciences, Bit Bio Limited, Replay Holdings, oNKo Innate, The Alliance for Cancer Gene Therapy (ACGT), Innate Pharma, and Shinobi Therapeutics. K.R. is the scientific founder of Syena.
